All In Biotech

Drug Trial Radar · NCT06751238

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 24, 2025

Primary completion

Oct 31, 2029

Study completion Mar 11, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA

Conditions

  • Juvenile Psoriatic Arthritis

Interventions

  • SecukinumabBiological

    Intravenous secukinumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum concentration on Day 1Time frame: Pre-infusion and end of infusion (EOI) at Day 1
  2. Maximum concentration at steady-state (Cmax, ss)Time frame: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
  3. Minimum concentration at steady-state (Cmin, ss)Time frame: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
  4. Area under the concentration-time curve at steady-state (AUCtau, ss)Time frame: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
  5. Average concentration at steady-state (Cavg,ss)Time frame: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University Health

    Loma Linda, California · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Ann and Robert H Lurie Childs Hosp

    Chicago, Illinois · Recruiting

  • Col Uni Med Center New York Presby

    New York, New York · Recruiting

  • Levine Childrens Hospital

    Charlotte, North Carolina · Recruiting

  • Cincinnati Childrens Hospital

    Cincinnati, Ohio · Recruiting

  • Univ Hosp Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Legacy Emanuel Research Hosp Portland

    Portland, Oregon · Recruiting

  • Childrens Hosp Pittsburgh UPMC

    Pittsburgh, Pennsylvania · Recruiting

  • Texas Arthritis Center

    El Paso, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.